REGRANEX (becaplermin gel 0.01%) by Smith and Nephew. Approved for human platelet-derived growth factor [epc]. First approved in 1997.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
REGRANEX (becaplermin gel 0.01%) is a topical human platelet-derived growth factor (PDGF) indicated for diabetic foot ulcers. It works by stimulating angiogenesis and granulation tissue formation to promote wound healing. The product is administered as a gel applied directly to the ulcer wound bed.
Product approaching loss of exclusivity with moderate Part D utilization; commercial teams should prepare for competitive erosion and potential transition strategies.
Human Platelet-derived Growth Factor
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Worked on REGRANEX at Smith and Nephew? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Smith and Nephew is hiring 5 roles related to this product
Working on REGRANEX offers significant commercial career opportunities with 322 linked positions, primarily in field sales and reconstruction specialty roles under Smith and Nephew sponsorship. The LOE-approaching lifecycle creates both defensive commercial roles and operational/manufacturing positions focused on cost optimization and production efficiency.
322 open roles linked to this drug
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo